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1. Introduction 
Endometrial cancer (EC) is the most common malignancy of the female genital tract. 
Overall, about 2% to 3% of women develop EC during their lifetime [Jemal et al., 2006]. EC 
is a malignancy that occurs primarily in postmenopausal women. 
Based on clinical and pathological features, EC is classified into 2 types [Bokhman, 1983]. 
Type I EC, represents the majority of sporadic EC cases (70-80%), is usually well 
differentiated and endometrioid in histology. Type II EC, represents the minority of 
sporadic EC cases (10-20%), is poorly differentiated and usually papillary serous or clear cell 
in histology [Bokhman, 1983; Lax, 2004; Doll et al., 2008]. 
The Epidermal Growth Factor system (EGF system) is present in human organs and play 
important role in embryogenesis and postnatal development [Casalini et al., 2004; Uberall et 
al., 2008]. 
Dysregulation of the EGF signaling network is implicated in various disorders [Marmor et 
al., 2004; Uberall et al., 2008]. In cancer, the EGF system contributes in proliferation, 
transformation, angiogenesis, migration and invasion [Holbro et al., 2003]. 
2. Epidermal growth factor system 
2.1 Receptors and ligands 
The EGF system is present in human organs and play important role in cell proliferation, 
differentiation and apoptosis during embryogenesis and postnatal development [Casalini et 
al., 2004; Uberall et al., 2008]. 
The EGF system has four receptors: epidermal growth factor receptor (EGFR) (also known 
as ErbB-1, HER1), ErbB-2 (also called HER2, Neu), ErbB-3 (also called HER3) and ErbB-4 
(also called HER4)] [Holbro et al., 2003; Yarden, 2001a; Yarden & Sliwkowski, 2001b]. 
ErbB receptors belong to subclass I of the superfamily of Receptor Tyrosine Kinases 
(RTKs) [Holbro et al., 2003; Uberall et al., 2008]. They are trans-membrane glycoproteins 
with an extracellular region containing two ligand-binding domains, an extracellular 
juxtamembrane region, a hydrophobic transmembrane domain and an intracellular 
domain with tyrosine kinase activity [Riese et al., 2007; Yarden, 2001a; Yarden & 
Sliwkowski, 2001b]. They catalyze the transfer of the Ǆ phosphate of ATP to hydroxyl 
groups of tyrosines in target proteins [Hunter, 1998]. ErbB-3 lacks intrinsic tyrosine kinase 
activity [Mass, 2004]. 
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The extracellular region of ErbB receptors has 4 subdomains (I-IV). Subdomains I and III 
(also called L1 and L2) are important for ligand binding. Subdomain II (also called S1) is 
important for dimerization between two receptors [Ogiso et al., 2002]. 
The EGF system has numerous ligands. According to their affinity for one or more ErbB 
receptors, they divided into three groups: 
1. The first group includes ligands with binding specificity for EGFR: EGF, transforming 
growth factor-a (TGF-a) and amphiregulin (AR) [Yarden, 2001a; Yarden & Sliwkowski, 
2001b; Holbro et al., 2003; Normanno et al., 2003;]. 
2. The second group includes ligands with dual binding specificity for EGFR and ErbB4: 
betacellulin (BTC), heparin-binding growth factor (HB-EGF) and epiregulin (EPR) 
[Yarden, 2001a; Yarden & Sliwkowski, 2001b; Holbro et al., 2003; Normanno et al., 
2003;]. 
3. The third group includes ligands with binding specificity for ErbB-3 and ErbB-4: 
neuregulins (NRGs) or heregulins (HRGs). They divided in two subgroups based on 
their ability to bind ErbB-3 and ErbB-4 (NRG-1 and NRG-2) or only ErbB-4 (NRG-3 and 
NRG-4) [Zhang et al., 1997; Harari et al., 1999; Yarden, 2001a; Yarden & Sliwkowski, 
2001b; Holbro et al., 2003; Normanno et al., 2003]. 
The ligands for ErbB receptors bind to the extracellular domain, resulting in receptor 
activation by homodimer and/or heterodimer formation and the subsequent 
transphosphorylation of tyrosine residues in the cytoplasmic region [Alroy & Yarden, 1997; 
Yarden, 2001a; Yarden & Sliwkowski, 2001b ; Holbro et al., 2003]. No direct ligand for ErbB-
2 has been described [Holbro et al., 2003]. 
2.2 ErbB receptors homodimerization and heterodimerization 
The extracellular region of EGFR, ErbB-3 and ErbB-4 has two distinct conformations: 
1. The closed conformation (inactive), has intramolecular interactions between 
subdomains II and IV [Ferguson et al., 2003; Dawson et al., 2005; Riese et al., 2007]. 
2. The open conformation (active), where subdomains I and III form a ligand-binding 
pocket that permits interactions between a single ligand and subdomains I and III 
[Ferguson et al., 2003; Dawson et al., 2005; Riese et al., 2007]. 
In the absence of ligand binding, the extracellular region of EGFR, ErbB-3 and ErbB-4 has 
equilibrium between closed and open conformation [Ferguson et al., 2003; Dawson et al., 
2005; Ozcan et al., 2006; Riese et al., 2007]. This equilibrium favours the closed conformation 
[Ozcan et al., 2006; Riese et al., 2007]. 
Ligand binding stabilizes extracellular region in the open conformation and leads to the 
formation of both homodimeric and heterodimeric ErbB receptor complexes [Olayioye et al., 
2000; Dawson et al., 2005; Ozcan et al., 2006; Riese et al., 2007]. The dimeric formation 
triggers receptor activation by an allosteric mechanism [Zhang et al., 2006]. That leads to 
intracellular kinase activation and initiation of downstream signaling pathways [Qian et al., 
1994; Olayioye et al., 2000; Yarden & Sliwkowski, 2001b]. 
The extracellular region of ErbB-2 has a conformation not suitable for ligand binding 
[Garrett et al., 2003]. However, this conformation allows extension of the receptor 
dimerization arm in subdomain II [Burgess et al., 2003; Garrett et al., 2003; Riese et al., 2007]. 
This suggests that ErbB-2 is capable for ligand independent dimerization and signaling 
[Riese et al., 2007]. ErbB-2 heterodimerizes with other ErbB receptors and it is their preferred 
heterodimerization partner [Hynes & Stern, 1994; Graus-Porta et al., 1997; Olayioye et al., 
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2000; Yarden & Sliwkowski, 2001b; Garrett et al., 2003]. At elevated expression levels ErbB-2 
homodimerizes [Garrett et al., 2003]. 
ErbB-3 lacks intrinsic tyrosine kinase activity and therefore can initiate signaling only in 
association with another ErbB receptor, usually ErbB-2 [Mass, 2004]. 
Although both homodimerization and heterodimerization result in activation of the EGF 
system network, heterodimers are more potent and mitogenic [Marmor et al., 2004]. ErbB-2 
and ErbB-3 heterodimer is the most transforming and mitogenic receptor complex and 
increases cell motility on stimulation with a ligand [Alimandi et al., 1995; Wallasch et al., 
1995; Yarden & Sliwkowski, 2001]. 
The dimerization of ErbB receptors represents the fundamental mechanism that drives 
transformation [Zhang et al., 2007]. 
2.3 ErbB receptors signaling 
Dimerization of ErbB receptors leads to intracellular kinase activation [Olayioye et al., 2000; 
Qian et al., 1994; Yarden & Sliwkowski, 2001b]. As a result, a number of tyrosine residues in 
the COOH-terminal portion of ErbB receptors become phosphorylated [Burgess et al., 2003; 
Holbro et al., 2003; Zhang et al., 2007]. These phosphorylated tyrosine residues function as 
docking sites for cytoplasmic proteins containing Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains [Songyang et al., 1993; Marmor et al., 2004; Yarden 
& Sliwkowski, 2001b; Zhang et al., 2007]. Recruitment of proteins initiates intracellular 
signaling via several pathways: 
2.3.1 Ras / Raf / mitogen-activated protein kinase (MAPK) pathway 
The Ras / Raf / mitogen-activated protein kinase (MAPK) pathway regulates cell 
proliferation and survival [Scaltriti & Baselga, 2006]. Following ErbB phosphorylation, the 
complex of Grb2 and Sos adaptor proteins binds directly or indirectly (through Shc adaptor 
protein) to specific intracellular ErbB docking sites [Lowenstein et al., 1992; Batzer et al., 
1994]. 
This interaction results in conformational modification of Sos, leading to recruitment of Ras-
GDP and subsequent Ras activation (Ras-GTP) [Hallberg et al., 1994]. Ras-GTP activates Raf-
1 and, through intermediate steps, phosphorylates MAPK-1 and MAPK-2 [Hallberg et al., 
1994; Liebmann, 2001]. Activated MAPKs phosphorylate and regulate specific intranuclear 
transcription factors involved in cell migration and proliferation [Hill & Treisman, 1995; 
Scaltriti & Baselga, 2006 Gaestel, 2006]. 
2.3.2 Phosphatidylinositol 3-kinase (PI3K) / Akt pathway 
The Phosphatidylinositol 3-kinase (PI3K) / Akt pathway regulates cell growth, apoptosis, 
tumor invasion, migration and resistance to chemotherapy [Vivanco & Sawyers, 2002; Shaw 
& Cantley, 2006]. 
PI3K is a dimeric enzyme that composed of a regulatory p85 subunit and a catalytic p110 
subunit [Vivanco & Sawyers, 2002]. The regulatory p85 subunit, is responsible of the 
anchorage to ErbB receptor specific docking sites, through interaction of its Src homology 
domain 2 (SH2) with phosphotyrosine residues [Yu et al, 1998a; Yu et al., 1998b]. The 
catalytic p110 subunit, catalyze the phosphorylation of phosphatidylinositol 4, 5 
diphosphate at the 3’ position [Vivanco & Sawyers, 2002]. Phosphatidylinositol 3, 4, 5 
triphosphate, phosphorylates and activates the protein serine/threonine kinase Akt [Stokoe 
et al., 1997; Vivanco & Sawyers, 2002]. 
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ErbB receptor specific docking sites for p85 subunit are present on ErbB-3 and absent on 
EGFR [Carpenter et al., 1993; Yarden & Sliwkowski, 2001b]. EGFR dependent PI3K 
activation occurs through dimerization of EGFR with ErbB-3 or through the docking protein 
Gab-1 [Mattoon et al., 2004; Scaltriti & Baselga, 2006]. 
2.3.3 Signal transducers and activators of transcription (STAT) pathway 
Signal transducers and activators of transcription (STAT) pathway regulates oncogenesis 
and tumor progression [Bromberg, 2002]. 
STAT proteins interact with phosphotyrosine residues via their Src homology domain 2 
(SH2) and, on dimerization, translocate to the nucleus and induce the expression of specific 
target genes [Haura et al., 2005; Yu et al., 2004; Zhong et al., 1994]. Constitutive activation of 
STAT proteins (especially STAT-3 and STAT-5) is present in various primary cancers 
[Bromberg, 2002; Haura et al., 2005]. 
EGFR regulate STAT pathway through a Janus kinase (JAK) or a JAK independent 
mechanism [Kloth et al., 2003; Andl et al., 2004]. Augmented activity of EGFR and ErbB-2, 
promote persistent STAT-3 activation and subsequently induce oncogenesis and tumor 
progression [Bromberg, 2002]. 
2.3.4 Src kinase pathway 
The Src kinase pathway regulates cell proliferation, migration, adhesion, angiogenesis, and 
immune function. 
Src is a member of a 10 gene family (FYN, YES, BLK, FRK, FGR, HCK, LCK, LYN, SRMS) of 
non-RTKs. It is located in the cytoplasm and cross-connected with other signaling pathways, 
such as PI3K and STAT pathway [Yeatman, 2004; Summy & Gallick, 2006;]. 
Although Src functions independently, it may interact with RTKs such as EGFR. The 
interaction between Src and EGFR may enhance ErbB signaling and may be involved in 
resistance to EGFR targeted therapy [Jorissen et al., 2003; Leu & Maa, 2003]. 
2.3.5 Phospholipase Cγ / protein kinase C pathway 
Phospholipase CǄ (PLCǄ) interacts directly with activated EGFR and ErbB-2 and hydrolyses 
phosphatidylinositol 4, 5 diphosphate  to inositol 1, 3, 5 triphosphate (IP3) and 1, 2 
diacylglycerol (DAG) [Chattopadhyay et al., 1999; Patterson et al., 2005]. 
IP3 is important for intracellular calcium release. DAG is cofactor in protein kinase C (PKC) 
activation. Activated PKC activates MAPK and c-Jun NH2-terminal kinase [Schönwasser et 
al., 1998; McClellan et al., 1999]. 
3. ErbB receptors and cancer 
3.1 The role of epidermal growth factor system in carcinogenesis 
Dysregulation of the EGF system signaling network is implicated in cancer, diabetes, 
autoimmune, inflammatory, cardiovascular and nervous system disorders [Marmor et al., 
2004; Uberall et al., 2008]. 
Loss of control of the cell functions mediated by the EGF system signaling network is a 
hallmark of oncogenesis, in which the balance between cell proliferation and differentiation 
is disturbed. Several types of human cancers associated with dysregulation of the EGF 
system signaling network [Uberall et al., 2008]. 
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The EGF system signaling network in cancer becomes hyperactivated with a range of 
mechanisms (ligand overproduction, receptor overproduction, constitutive receptor 
activation) [Marmor et al., 2004; Salomon et al, 1995; Yarden & Sliwkowski, 2001b]. It is also 
contributes in proliferation, transformation, angiogenesis, migration and invasion [Holbro et 
al., 2003]. 
 
 
Fig. 1. ErbB receptors signalling. 
3.2 Expression of ErbB receptors in cancer 
Overexpression and structural alterations of EGFR are frequent in head, neck, esophageal, 
breast, lung, gastric, liver, kidney, colorectal, prostate, bladder and ovarian cancer 
[Moscatello et al., 1995; Yarden & Sliwkowski, 2001b; Uberall et al., 2008]. They associated 
with higher grade, disease progression, poor survival and resistance to radiotherapy and 
chemotherapy [Yarden & Sliwkowski, 2001b; Lurje & Lenz, 2009]. 
Overexpression of ErbB-2 is frequent in head, neck, breast, lung, pancreatic, esophageal, 
liver, colorectal, prostate, bladder, ovarian, endometrial and cervical cancer [Odicino et al.; 
Ross & Fletcher, 1998; Yarden & Sliwkowski, 2001b; Uberall et al., 2008]. It is an indicator of 
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a more aggressive clinical behavior [Ross & Fletcher, 1998; Yarden & Sliwkowski, 2001b; 
Odicino et al., 2008]. 
Overexpression of ErbB-3 is frequent in head, neck, breast, gastric, liver, colorectal, prostate 
and ovarian cancer [Yarden & Sliwkowski, 2001b; Uberall et al., 2008]. Although ErbB-3 
overexpression related with ErbB-2 positivity and lymph node involvement, a definitive 
relationship with survival has not been established [Lemoine et al., 1992; Gasparini et al., 
1994; Bièche et al., 2003]. 
Overexpression of ErbB-4 is frequent in head, neck, lung and liver cancer [Yarden & 
Sliwkowski, 2001b; Uberall et al., 2008]. It is related with favorable prognosis in breast and 
bladder cancer [Suo et al., 2002; Memon et al., 2004; Barnes et al., 2005]. 
4. ErbB receptors and endometrial cancer 
4.1 Endometrial cancer classification 
EC is the most common malignancy of the female genital tract. Overall, about 2% to 3% of 
women develop EC during their lifetime [Jemal et al., 2006]. EC is a malignancy that occurs 
primarily in postmenopausal women. Based on clinical and pathological features, EC is 
classified into 2 types [Bokhman, 1983]: 
1. Type I EC, represents the majority of sporadic EC cases (70-80%). It is usually well 
differentiated and endometrioid in histology [Bokhman, 1983; Lax, 2004 Doll et al., 
2008]. It is estrogen-related, usually arises from endometrial hyperplasia, has less 
aggressive clinical course and favorable prognosis [Bokhman, 1983; Sherman et al., 
1997; Doll et al., 2008]. Type I EC overexpress genes hormonally regulated during the 
menstrual cycle and involved in endometrial homeostasis (MGB2, LTF, END1, MMP11) 
[Moreno-Bueno et al., 2003; Risinger et al., 2003]. It is also associated with defects in 
DNA mismatch repair, microsatelite instability MLH1/MSH6 and specific mutations in 
PTEN, K-ras and ǃ-catenin genes [Basil et al., 2000; Lax et al., 2000; Lax, 2004; Hecht & 
Mutter, 2006; Bansal et al., 2009]. 
2. Type II EC, represents the minority of sporadic EC cases (10-20%). It is poorly 
differentiated and usually papillary serous or clear cell in histology [Bokhman, 1983; 
Lax, 2004 Doll et al., 2008]. It is not estrogen-related, arises from atrophic endometrium, 
has aggressive clinical course and propensity for early spread and poor prognosis 
[Bokhman, 1983; Abeler & Kjorstad, 1991; Goff et al, 1994]. 
Type II EC overexpress genes involved in the regulation of the mitotic spindle checkpoint 
and associated with aneuploidy and aggressive clinical behavior (STK15, BUB1, CCNB2) 
[Moreno-Bueno et al., 2003; Risinger et al., 2003 Hecht & Mutter, 2006]. It is also associated 
with mutations in p53 gene, inactivation of p16, ErbB-2 amplification/overexpression and 
decreased expression of E-cadherin [Hetzel et al., 1992; Tashiro et al. 1997; Lax et al., 2000; 
Holcomb et al., 2002; Lax, 2004;  Santin et al., 2005; Hecht & Mutter, 2006;  Grushko et al., 
2008; Bansal et al., 2009]. 
4.2 Expression and clinical significance of ErbB receptors in endometrial cancer 
Due to the inactive status of postmenopausal endometrium, it is expectable to find 
significantly higher expression of the 4 ErbB receptors in EC tissue [Ejskjaer et al., 2007]. 
EGFR, in endometrium, is localized to the basal part of surface epithelial cells, only in 
stromal cells, or both to epithelial and stromal cells [Bigsby et al., 1992; Wang et al., 1994; 
Imai et al., 1995; Möller et al., 2001; Ejskjaer et al., 2005]. It is primarily located to the cell 
membrane but also to the cytoplasm [Nyholm et al., 1993; Reinartz et al., 1994; Khalifa et al., 
1994; Niikura et al., 1996; Ejskjaer et al., 2007]. 
www.intechopen.com
 
The Role of ErbB Receptors in Endometrial Cancer 
 
29 
In unselected patients with EC, it has been reported EGFR expression in 43–67% of cases 
[Reinartz et al., 1994; Khalifa et al., 1994; Scambia et al, 1994; Niikura et al., 1996; 
Androutsopoulos et al., 2006; Adonakis et al., 2008]. In patients with type I EC, it has been 
reported EGFR expression in 46% of cases. In patients with type II EC, it has been reported 
EGFR expression in 34% of cases [Konecny et al., 2009]. 
Although the clinical significance of EGFR has not been studied well in EC, it may have a 
dual role. EGFR overexpression did not affect disease progression in type I EC, although 
affects disease progression in type II EC. EGFR overexpression in type II EC associated with 
high grade and adverse clinical outcome [Konecny et al., 2009]. 
ErbB-2, in endometrium, is localized baso-laterally in the glands and surface epithelial cells 
[Bigsby et al., 1992; Wang et al., 1994; Miturski et al., 1998; Ejskjaer et al., 2005]. It is located 
to the cell membrane [Reinartz et al., 1994; Khalifa et al., 1994; Ejskjaer et al., 2007; Odicino et 
al., 2008]. 
In unselected patients with EC, ErbB-2 amplification/overexpression represents a rare event. 
In patients with type I EC, it has been reported ΕrbB-2 receptor overexpression in 8% of cases 
and ErbB-2 gene amplification in 1.4-3% of cases [Morrison et al., 2006; Konecny et al., 2009]. 
Although, ΕrbB-2 amplification/overexpression is more common in patients with type II 
EC, the exact frequency remains controversial. In patients with papillary serous EC, it has 
been reported ΕrbB-2 receptor overexpression in 18%-80% of cases and ΕrbB-2 gene 
amplification in 17-47% of cases [Santin et al., 2005; Morrison et al., 2006; Slomovitz et al., 
2008; Grushko et al., 2008; Konecny et al., 2009;]. In patients with clear cell EC, it has been 
reported ΕrbB-2 receptor overexpression in 33% of cases and ΕrbB-2 gene amplification in 
16-50% of cases [Morrison et al., 2006; Grushko et al., 2008; Konecny et al., 2009]. ΕrbB-2 
overexpression especially in type II EC, is an indicator of a highly aggressive disease and a 
poor overall survival [Lukes et al., 1992; Santin et al., 2005; Morrison et al., 2006; Odicino et 
al., 2008]. 
ErbB-3, in endometrium, is localized to surface epithelial cells [Prigent et al., 1992; 
Srinivasan et al., 1999 Ejskjaer et al., 2005]. It is located to the cytoplasm, with membrane 
staining in a minority of samples [Srinivasan et al., 1999; Ejskjaer et al., 2007]. 
The clinical significance of ErbB-3 has not been studied well in EC [Srinivasan et al., 1999; 
Androutsopoulos et al., 2006; Ejskjaer et al., 2007; Adonakis et al., 2008]. 
ErbB-4, in endometrium, is localized to epithelial and stromal cells [Srinivasan et al., 1999; 
Chobotova et al., 2005; Ejskjaer et al., 2005]. It is located to the cytoplasm, with membrane 
staining in a minority of samples [Srinivasan et al., 1999; Ejskjaer et al., 2007;]. 
The clinical significance of ErbB-4 has not been studied well in EC [Srinivasan et al., 1999; 
Androutsopoulos et al., 2006; Ejskjaer et al., 2007; Adonakis et al., 2008]. 
4.3 Endometrial cancer and ErbB-targeted therapies 
EGFR and ErbB-2 as targets for cancer therapy have been investigated for over 20 years. 
Two major classes of ErbB-targeted therapies have been developed. 
4.3.1 Anti-ErbB monoclonal antibodies (MoAbs) 
1. Anti-EGFR MoAbs (cetuximab, panitumumab) bind to the extracellular domain of 
EGFR and prevent ligand binding and ligand dependent receptor activation. 
2. Anti-ErbB-2 MoAb (trastuzumab) binds to the extracellular domain of ErbB-2 and 
interferes with ligand independent receptor activation, but the exact mechanism of 
action is still subject of ongoing debate [Baselga & Arteaga, 2005; Lurje & Lenz, 2009]. 
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3. There is a new class of Anti-ErbB MoAb (pertuzumab) that prevent receptor 
heterodimerization [Baselga & Arteaga, 2005]. 
4.3.2 ErbB-specific tyrosine kinase inhibitors (TKIs) 
TKI block the binding of adenosine triphosphate to the intracellular domain of EGFR 
(gefitinib, erlotinib) or EGFR and ErbB-2 (lapatinib) and blocks ErbB activity and subsequent 
intracellular signaling [Baselga & Arteaga, 2005; Lurje & Lenz, 2009]. 
4.3.3 Effectiveness of ErbB-targeted therapies 
Overall response rate to these drugs is modest, unless they are associated with 
chemotherapy or radiotherapy [Baselga & Arteaga, 2005]. ErbB-targeted therapies have not 
been clinically tested in type II EC [Konecny et al., 2009]. Preclinical data suggest that ErbB-
targeted therapies may be clinically active in well-defined subgroups of type II EC patients 
with EGFR and ErbB-2 overexpression [Villella et al., 2006; Jewell et al., 2006; Konecny et al., 
2008; Santin et al., 2008; Vandenput et al., 2009; El-Sahwi et al., 2010;]. 
The role of ErbB-targeted therapies in EC should be further investigated in clinical trials to 
evaluate their therapeutic efficacy [Odicino et al., 2008; Oza et al., 2008; Santin et al., 2008; 
Konecny et al., 2009; Fleming et al., 2010; Santin, 2010]. Also, further studies into the 
molecular pathways of EC development and progression, will increase our knowledge of 
this disease and will lead to the discovery of new generation molecules with higher 
therapeutic efficacy. 
5. Conclusion 
Additional studies into the molecular pathways of EC development and progression, will 
increase our knowledge of this disease and will lead to the discovery of new generation 
molecules with higher therapeutic efficacy. 
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scope of the text is not basic, but rather aims to provide a comprehensive and updated source of advances in
the diagnosis and therapeutic strategies in this field of gynecologic cancer. Each section in the book attempts
to provide the most relevant evidence-based information in the biology and genetics, modern imaging, surgery
and staging, and therapies for endometrial cancer. It is hoped that future editions will bring additional authors
to contribute to this endeavor. To this end, it is our patients who will benefit from this work.
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